Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Open Access
- 16 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Obesity
- Vol. 36 (6), 843-854
- https://doi.org/10.1038/ijo.2011.158
Abstract
Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years. A randomized, double-blind, placebo-controlled 20-week study with 2-year extension (sponsor unblinded at 20 weeks, participants/investigators at 1 year) in 19 European clinical research centers. A total of 564 adults (n=90-98 per group; body mass index 30-40 kg m(-2)) enrolled, 398 entered the extension and 268 completed the 2-year trial. Participants received diet (500 kcal deficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg, n=90-95), placebo (n=98) or open-label orlistat (120 mg × 3, n=95). After 1 year, liraglutide/placebo recipients switched to liraglutide 2.4 mg, then 3.0 mg (based on 20-week and 1-year results, respectively). The trial ran from January 2007-April 2009 and is registered with Clinicaltrials.gov, number NCT00480909. From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.7-8.0) more weight than those on placebo and 3.8 kg (1.6-6.0) more than those on orlistat (P0.0001; intention-to-treat, last-observation-carried-forward). At year 2, participants on liraglutide 2.4/3.0 mg for the full 2 years (pooled group, n=184) lost 3.0 kg (1.3-4.7) more weight than those on orlistat (n=95; P<0.001). Completers on liraglutide 2.4/3.0 mg (n=92) maintained a 2-year weight loss of 7.8 kg from screening. With liraglutide 3.0 mg, 20-week body fat decreased by 15.4% and lean tissue by 2.0%. The most frequent drug-related side effects were mild to moderate, transient nausea and vomiting. With liraglutide 2.4/3.0 mg, the 2-year prevalence of prediabetes and metabolic syndrome decreased by 52 and 59%, with improvements in blood pressure and lipids. Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.Keywords
This publication has 33 references indexed in Scilit:
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsThe New England Journal of Medicine, 2010
- Changes in Inflammatory Biomarkers Across Weight Classes in a Representative US Population: A Link Between Obesity and InflammationJournal of Gastrointestinal Surgery, 2009
- Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabetic Medicine, 2008
- Can we predict future improvement in glycaemic control? Response to Singh and Press, 2008Diabetic Medicine, 2008
- Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 DiabetesDiabetes Care, 2007
- Definition of Metabolic SyndromeCirculation, 2004
- Long-term pharmacotherapy for obesity and overweightEmergencias, 2003
- World Medical Association Declaration of HelsinkiJAMA, 2000
- Executive SummaryObesity Research, 1998
- A Multiple Comparison Procedure for Comparing Several Treatments with a ControlJournal of the American Statistical Association, 1955